CompletedNCT01942161
A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
Researchers compared Aripiprazole Low (2 mg/day), Aripiprazole Mid (6 - 12 mg/day) and Aripiprazole High (24 - 30 mg/day) to find out how the approaches affected psychotic symptoms in children with schizophrenia.
Medication studyAges 13–17Japan
Understand this study
What did researchers investigate?
Researchers compared Aripiprazole Low (2 mg/day), Aripiprazole Mid (6 - 12 mg/day) and Aripiprazole High (24 - 30 mg/day) to find out how the approaches affected psychotic symptoms in children with schizophrenia.
Who was this study for?
Listed age limits: 13 years to 17 years.
- Listed locations
- Chubu Region and 7 more locationsSee all locations and recruitment
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateAugust 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 106
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2, Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Japan
- Age range
- From 13 Years to 17 Years
- Official registry ID
- NCT01942161
- Official title
Show the full official title
A Multicenter, Double-blind, Randomized, Dose-comparison Study of Three Different Doses of Aripiprazole (2 mg/Day, 6-12 mg/Day, 24-30 mg/Day) Orally Administered Over 6 Weeks in Pediatric Patients (Aged 13-17 Years) With Schizophrenia
Recruitment & locations
CompletedChubu Region · Chugoku Region · Hokkaido Region
5 more locations
- Kansai Region
- Kanto Region
- Kyushu Region
- Shikoku Region
- Tohoku Region
Questions about this study
What did researchers investigate?
Researchers compared Aripiprazole Low (2 mg/day), Aripiprazole Mid (6 - 12 mg/day) and Aripiprazole High (24 - 30 mg/day) to find out how the approaches affected psychotic symptoms in children with schizophrenia.
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Co., Ltd., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole Low (2 mg/day), Aripiprazole Mid (6 - 12 mg/day) and Aripiprazole High (24 - 30 mg/day).
Who was this study for?
Listed age limits: 13 years to 17 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me